BC Week In Review | Apr 6, 2015
Clinical News

Cis-UCA Eye Drops: Completed Phase II enrollment

Herantis completed enrollment of 161 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 1% and 2.5% cis-UCA Eye Drops for 4 weeks. Herantis Pharma pl c (HSE:HRTIS), Helsinki, Finland   Product: Cis-UCA Eye...
Items per page:
1 - 1 of 1